SEC Form 4 · accession 0001127602-18-004173
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Norbert W Bischofberger
Officer — EVP, R&D and CSO
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $83.49 | Feb 1, 2018 | A | 94,360 | A | — | Feb 1, 2028 | Common Stock | 94,360 | 94,360 | D |
Explanation of responses
- F1The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.